Suraksha Diagnostic reports strong growth in Q2 and H1 FY25 financial results

Kolkata, 20 December 2024 – Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, has reported robust financial performance for the second quarter and the first half of the fiscal year 2024–25. The company demonstrated significant growth in revenue, profitability, and operational efficiency, emphasizing its leading position in the diagnostic industry.

Financial Performance Overview

For the first half of FY25, Suraksha Diagnostic reported a total income of ₹1,299.2 million, marking a 14.5% year-over-year (YoY) increase. The EBITDA grew by 24.9% to ₹462.3 million, with margins improving by over 300 basis points YoY to 36.3%. The company’s Profit After Tax (PAT) surged 45.3% YoY to ₹178.2 million, reflecting strong operational efficiency and a focus on sustainable growth.

In Q2 FY25, the total income stood at ₹680.7 million, a 12.3% YoY increase. EBITDA for the quarter was ₹245.1 million, representing a 14.6% YoY growth, while the EBITDA margin reached 36.7%, up from 35.6% in Q2 FY24. PAT for the quarter grew 21.8% YoY to ₹101.6 million.

Strategic Insights and Operational Highlights

Joint Managing Director and CEO, Ms. Ritu Mittal, attributed the strong financial results to the company’s commitment to operational efficiency and revenue growth. She noted that the increasing shift in consumer preferences toward organized diagnostic chains has been a key driver of the company’s performance.

Suraksha Diagnostic has consistently improved its revenue per patient and EBITDA per patient, which stood at ₹2,099 and ₹761, respectively, during H1 FY25. The company continues to solidify its presence in West Bengal, which accounts for 47 out of its 51 operational centres, and has plans to expand further into Eastern and North-Eastern India.

Growth Strategies and Future Outlook

Suraksha Diagnostic is focused on enhancing shareholder value through targeted expansion and exploring inorganic growth opportunities. The company’s strategy includes leveraging its established network in core markets and investing in advanced diagnostic technologies to improve service quality.

As a part of its commitment to quality, Suraksha Diagnostic operates a central reference laboratory accredited by the College of American Pathologists and three laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). Additionally, its diagnostic centres hold accreditation from the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Industry Context and Challenges

Despite its achievements, the company acknowledged potential risks, including economic fluctuations, regulatory changes, and technological advancements. It emphasized its focus on adaptability and resilience to navigate these challenges effectively.

Suraksha Diagnostic’s performance in Q2 and H1 FY25 underscores its robust operational model and strategic focus on growth. The company is well-positioned to capitalize on the growing demand for organized diagnostic services and continues to set benchmarks in the healthcare diagnostics sector.